ERBB2 and neoplasm: To better understand the underlying differences between TN and HR + HER2− immune-high and -low clusters, we used gene signatures for CD8+ (Fig. 3Ai) and CD4+ Treg (Fig. 3Aii) T cells as proxy for immune cell type abundance in the tumor.